Stock Ratings / Health Care / OFIX / dividends

EMBC (68) MOBI (50) SI (44) CLPT (19) ⌘ Pro Terminal →

Orthofix Medical Inc. (OFIX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is OFIX trading relative to its 50-day, 200-day, and 52-week technical levels?

OFIX last traded at $9.07 (-11.43% on volume of 657,871 shares), positioning the stock -3.30% below its 50-day simple moving average ($9.38) and -17.92% below its 200-day simple moving average ($11.05). Across its 52-week range of $8.50 to $16.99, OFIX sits at the 6.7% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($8.21 to $9.93).

Q: Does OFIX pay a dividend and is it safe?

Orthofix Medical Inc. (OFIX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$9.07 -11.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.87

Orthofix Medical Inc. (OFIX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $369.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OFIX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Orthofix Medical Inc. (NASDAQ: OFIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $9.07 (-11.43% 1D, market cap $369.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, OFIX ranks #425 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OFIX compare to EMBC and MOBI in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), OFIX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 68.8%, and ROIC of -12.2%. By comparison, EMBC (Embecta Corp.) holds a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M) and MOBI (Mobia Medical Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OFIX?

▼

Per OFIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000884624), Orthofix Medical Inc. generated $822.3M in revenue (+2.9% YoY), -$92.2M in net income, and $33.3M in free cash flow against $850.6M in total assets and $157.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.87 (-2.25%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OFIX)Realized 20D OHLCV Swing Band: ±9.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY OFIX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 1.02 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$9.26+6.4% Next Q

Q2 (-2Q)

Grade D$9.85-1.4% Next Q

Q3 (-1Q)

Grade D$9.71-6.6% Next Q

Current

Grade D-$9.07-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OFIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OFIX currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.38) and Max Pain ($9.52) forces dealer call-delta covering toward $17.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OFIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OFIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OFIX)

✓Walkthrough of OFIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OFIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.48%▼ DESCENDING CHANNEL

2026-11-03O $10.24H $10.24L $9.07C $9.07VOL 657.9K

RES: $10.56SUP: $8.32SMA50: $9.38SMA200: $11.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OFIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OFIX Butterfly Map → + Track OFIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OFIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OFIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OFIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OFIX)

Health Care Rank #425 of 1016 ⚔️ EMBC vs OFIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OFIX vs. EMBC, MOBI, SI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Orthofix Medical Inc. (OFIX) ranks #425 by composite RQD confidence (42/100, grade D-) and #487 by equity capitalization ($369.4M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with OFIX at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OFIX ACTIVE Orthofix Medical Inc.	D-	42/100	—	68.8%	-12.2%	-11.43%	$369.4M	Benchmark Subject
EMBC Embecta Corp.	C+	68/100	3.9x	62.6%	35.5%	-4.73%	$354.1M	/embc-vs-ofix →
MOBI Mobia Medical Inc.	D	50/100	—	—	—	-6.12%	$352.2M	/mobi-vs-ofix →
SI Shoulder Innovations Inc.	D	44/100	—	76.5%	-16.1%	-6.41%	$398.3M	/si-vs-ofix →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	-0.19%	$342.0M	/clpt-vs-ofix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000884624

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Orthofix Medical Inc. (OFIX) reported GAAP revenue of $822.3M (+2.9% vs. FY2024 revenue of $799.5M , and +10.1% cumulative change since FY2023) , GAAP net income of -$92.2M, operating cash flow of $33.3M, and free cash flow of $33.3M (+29.3% YoY). On the balance sheet, OFIX closed FY2025 with $850.6M in total assets against $157.4M in total debt (Altman Z-Score: 1.02, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$822.3M	-$92.2M	$33.3M	$33.3M	$850.6M	$157.4M
FY2024 (FY)	2024-12-31	$799.5M	-$126.0M	$25.8M	$25.8M	$893.3M	$157.0M
FY2023 (FY)	2023-12-31	$746.6M	-$151.4M	-$45.8M	-$45.8M	—	—

3. OFIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OFIX compare to EMBC and MOBI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OFIX?

Where is OFIX trading relative to its 50-day, 200-day, and 52-week technical levels?

OFIX last traded at $9.07 (-11.43% on volume of 657,871 shares), positioning the stock -3.30% below its 50-day simple moving average ($9.38) and -17.92% below its 200-day simple moving average ($11.05). Across its 52-week range of $8.50 to $16.99, OFIX sits at the 6.7% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($8.21 to $9.93).

OFIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does OFIX pay a dividend and is it safe?

Orthofix Medical Inc. (OFIX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: OFIX RQD Cockpit OFIX 12M Forecast OFIX Earnings & Move OFIX Dividends & DRIP OFIX Insiders & 13F OFIX Whale Options OFIX Profit Sankey OFIX News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OFIX — Orthofix Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:36:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

The RQD Score is 47 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine (8 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of -12.2% and an FCF yield of 7.99%. Negative ROIC means the business is not currently earning returns above its cost of capital, while the positive FCF yield indicates some cash generation relative to market value.
Whale 13F Flow (9 / 20): Scored on institutional accumulation and options positioning. The underlying 13F detail is not provided in the source data.
Insider Conviction (11 / 20): Scored on SEC Form 4 and Congressional PTR cluster flow. The underlying trade detail is not provided in the source data.
Macro Regime Fit (9 / 20): Per the Roarable RQD rating, beta is 1.0 and the score reflects sector sensitivity.
Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 1.02, Piotroski F is 7/9, and Debt/Equity is 0.35.

For a prospective investor, the aggregate picture is weak. The highest-scoring pillar (insider conviction, 11/20) is still below half marks, and the two weakest pillars (cash engine and macro fit, 8 and 9 out of 20) point to the core difficulty: the business is currently loss-making at the operating line, so the stock's upside case depends on a turnaround that the rating does not yet credit. The balance-sheet pillar is moderate: the Piotroski reading is comparatively healthy, but the Altman Z reading of 1.02 sits in a range typically associated with financial distress, which constrains the valuation case. The verdict label itself flags distribution risk, so a prospective investor should weigh the downside signals heavily relative to the price-momentum evidence in the news feed.

Business

Orthofix Medical Inc. (OFIX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry (per the company profile). Per the market data, gross margin is 68.8%, which indicates the product mix carries high gross profitability. The source data does not describe the specific products, customers, or revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$822.3M	$-81.4M	$-92.2M	N/A	$33.3M	$82.0M	$157.4M
FY 2024	$799.5M	$-84.6M	$-126.0M	N/A	$25.8M	$83.2M	$157.0M
FY 2023	$746.6M	$-139.1M	$-151.4M	N/A	$-45.8M	N/A	N/A

Per the SEC financials, revenue grew from $746.6M (FY 2023) to $822.3M (FY 2025), while operating and net losses narrowed over the same span. Per the market data, the operating margin is -9.9% and the net margin is -11.2%. Per the Roarable RQD rating, ROIC is -12.2%, the Altman Z-Score is 1.02, and the Piotroski F-Score is 7/9. Debt/Equity is 0.35 per the Roarable RQD rating. Reported FY 2025 cash of $82.0M against debt of $157.4M shows the company carries net debt in the source figures.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items include:

Governance / legal watch (YELLOW): Two items reference possible breaches of fiduciary duties by insiders or officers and directors, including an investigation notice from a plaintiff firm. These are flagged as risk items; the source data does not establish any finding.
Earnings catalyst (YELLOW): The company announced it will report third-quarter 2026 financial results. The results themselves are not in the source data.
Product/fair-value catalyst (GREEN): A Yahoo Finance item is framed around a competitor (OrthoPediatrics) and references higher growth and new product wins; it is the only GREEN-flagged item.
Segment analysis (YELLOW): A Simply Wall St item states that roughly 80% of spine sales drive the upside. The percentage is as reported in the headline summary.

The Butterfly supply-chain graph reports no supply chain links and no proprietary signals.

Open Questions

What are the EPS and P/E figures, given that EPS and all valuation multiples are missing from the source data?
What is the outcome and scope of the reported governance and fiduciary-duty investigation?
What are the Q3 2026 results and do they confirm or reverse the FY 2025 operating loss trend?
What products and customers drive the 68.8% gross margin, and what share of revenue comes from spine?
What is the composition of the reported debt and how does it relate to the Altman Z-Score reading of 1.02?

OFIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Orthofix Medical Inc. (OFIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OFIX Debate Forum (3) ↓

🟡 MARKET WIRE Morningstar • 18h ago

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Morningstar report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Orthofix Medical Inc. Estimates – NASDAQ:OFIX

TradingView report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

OrthoPediatrics (KIDS) Stock Sees Fair Value Lift After Higher Growth And New Product Wins

Yahoo Finance report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 1d ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

PR Newswire report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Orthofix to Report Third Quarter 2026 Financial Results

Business Wire report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

OFIX: 80% Of Spine Sales Drive The Upside, Smaller Channels Still Decide It

Simply Wall St report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(OFIX) Movement as an Input in Quant Signal Sets

Stock Traders Daily report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Orthofix Medical stock sits 41.79 percent below its yearly high with USD 399.8 million value

ad-hoc-news.de report covering Orthofix Medical Inc. (OFIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OFIX Bull vs. Bear Conversation Board — What's Your Call at $9.07?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OFIX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $11.06 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OFIX (D • RQD 47/100) a Buy at $10.24?

Welcome to the OFIX (Orthofix Medical Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.99 (-22.0%)

Spot @ $10.24

Pump the brakes on OFIX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OFIX, but look at what you are paying: current EV/EBITDA multiples with 68.8% gross margins. Unless Orthofix Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.80 (+25.0%)

Spot @ $10.24

OFIX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OFIX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $10.24 (52-wk range $8.50 - $16.99), any beat on forward guidance forces shorts and underweight funds to chase.